Jump to content

User:Mr. Ibrahem/Rivaroxaban

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Rivaroxaban
Clinical data
Trade namesXarelto, others
Other namesBAY 59-7939
AHFS/Drugs.comMonograph
MedlinePlusa611049
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Bioavailability80–100%; Cmax = 2–4 hours (10 mg oral)[1]
MetabolismCYP3A4, CYP2J2 and CYP-independent mechanisms[1]
Elimination half-life5–9 hours in healthy subjects aged 20 to 45[1][2]
Excretion⁠2/3⁠ metabolized in liver and ⁠1/3⁠ eliminated unchanged[1]
Identifiers
  • (S)-5-chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl)
    phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide
Chemical and physical data
FormulaC19H18ClN3O5S
Molar mass435.88 g·mol−1
3D model (JSmol)
  • O=C1COCCN1c2ccc(cc2)N3C[C@@H](OC3=O)CNC(=O)c4ccc(s4)Cl
  • InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1 checkY
  • Key:KGFYHTZWPPHNLQ-AWEZNQCLSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots.[4] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery.[4] It is taken by mouth.[4]

Common side effects include bleeding.[4] Other serious side effects may include spinal hematoma and anaphylaxis.[4] It is unclear if use in pregnancy and breastfeeding is safe.[5] Compared to warfarin it has fewer interactions with other medications.[6] It works by blocking the activity of the clotting protein factor Xa.[4]

Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011.[7] It is on the World Health Organization's List of Essential Medicines as an alternative to dabigatran.[8] In the United States, it will not be available as a generic medication until 2024.[9][10] A month supply in the United Kingdom costs the NHS about £50 as of 2020.[11] In the United States, the wholesale cost of this amount is about US$430.[12] In 2017, it was the 109th most commonly prescribed medication in the United States, with more than six million prescriptions.[13][14]

References[edit]

  1. ^ a b c d "Xarelto: Summary of Product Characteristics". Bayer Schering Pharma AG. 2008. Archived from the original on 2010-07-27. Retrieved 2009-02-11.
  2. ^ Turgeon, Mary Lou (2018). "28. Disorders of haemostats and thrombosis: blood coagulation factors, hyper coagulable state, and anticoagulant therapy". Clinical Hematology: Theory & Procedures, Enhanced Edition (6th ed.). Burlington: Jones & Bartlett Learning. pp. 575–576. ISBN 978-1-284-29449-1. Archived from the original on 2021-08-28. Retrieved 2021-03-20.
  3. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 18 August 2020. Retrieved 6 September 2020.
  4. ^ a b c d e f "Rivaroxaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 3 March 2019.
  5. ^ "Rivaroxaban Use During Pregnancy". Drugs.com. Archived from the original on 27 March 2019. Retrieved 3 March 2019.
  6. ^ Kiser, Kathryn (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438. Archived from the original on 2019-03-27. Retrieved 2019-03-27.
  7. ^ "Generic Xarelto Availability". Drugs.com. Archived from the original on 16 June 2018. Retrieved 9 May 2017.
  8. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  9. ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Archived from the original on 2020-09-13. Retrieved 2019-04-24.
  10. ^ "Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug". 2019-04-22. Archived from the original on 2019-08-01. Retrieved 2019-04-24.
  11. ^ BNF (80 ed.). London: BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. pp. 137–139. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  12. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  13. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
  14. ^ "Rivaroxaban - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Rivaroxaban&oldid=1233639927"